文献速递内脏/肾动脉与血管畸形

动脉粥样硬化性慢性肠系膜缺血的血管内支架治疗:技术与中期结局

Endovascular Stenting for Atherosclerotic Chronic Mesenteric Ischemia: Technical and Midterm Outcomes.
PubMed 文献 · Ann Vasc Surg · 2026-06-26

该回顾性单中心研究纳入27例动脉粥样硬化性慢性肠系膜缺血患者,评估尝试性肠系膜上动脉血管内血运重建的技术结局、早期症状缓解、中期通畅率及围手术期安全性。技术成功率达92.6%,4周VAS评分中位数从8降至1(P<0.001),12个月Kaplan-Meier估计一期通畅率为90.7%。

要点

  • 尝试性SMA血管内支架治疗动脉粥样硬化性CMI技术成功率高(92.6%)。
  • 术后4周疼痛VAS评分显著降低,中位下降7.5分(95%CI 6.5-8.0)。
  • 12个月一期通畅率90.7%,无主要肠系膜动脉并发症或CMI相关死亡。

核心结论

  • 在动脉粥样硬化性CMI患者中,尝试性SMA血管内血运重建获得高技术成功率、显著早期症状缓解和良好中期通畅率。
  • VAS评估可作为以患者为中心的定量指标,补充基于影像的随访。

研究设计与样本

  • 回顾性单中心研究,纳入2020年9月至2025年9月期间尝试性接受SMA血管内血运重建的成人患者。
  • 排除血管炎相关肠系膜疾病后,27例动脉粥样硬化性CMI患者构成意向治疗队列。

主要发现

  • 27例中25例(92.6%)获得技术成功,包括10/10例狭窄和15/17例闭塞。
  • 23例有配对VAS数据,中位VAS评分从基线8(IQR 8-9.5)降至4周时1(IQR 0-2),P<0.001,Hodges-Lehmann中位下降7.5分(95%CI 6.5-8.0)。
  • 中位随访16个月(IQR 12-20),Kaplan-Meier估计12个月一期通畅率90.7%,辅助一期通畅率92.0%,二期通畅率100%。
  • 未发生主要肠系膜动脉并发症、肠切除、CMI相关死亡或支架闭塞相关死亡。

关键数值与推荐

  • 技术成功定义为残余狭窄<30%且顺行血流。
  • 疼痛负担采用10分VAS在基线和4周评估。
  • 支架通畅通过双功超声评估,必要时行CT血管造影,采用Kaplan-Meier分析估计。

临床怎么用

  • 对于动脉粥样硬化性CMI,可考虑尝试性SMA血管内支架治疗以实现高技​​术成功和症状缓解。
  • 术后可采用VAS评分作为定量患者报告指标,辅助影像学随访评估疗效。

局限性

  • 回顾性单中心设计,样本量较小(27例),随访时间中期。
  • 部分患者(23/27)有配对VAS数据,存在数据不完整可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate technical outcomes, early symptom relief, midterm patency, and periprocedural safety after attempted endovascular superior mesenteric artery (SMA) revascularization for atherosclerotic chronic mesenteric ischemia (CMI). METHODS: This retrospective single-center study included adults who underwent attempted endovascular SMA revascularization between September 2020 and September 2025. After exclusion of vasculitis-associated mesenteric disease, 27 patients with atherosclerotic CMI formed the intention-to-treat cohort. Technical success was defined as residual stenosis <30% with antegrade flow. Pain burden was assessed using a 10-point VAS at baseline and 4 weeks. Stent patency was assessed by duplex ultrasound, with computed tomography angiography when indicated, and estimated using Kaplan-Meier analysis. RESULTS: Technical success was achieved in 25 of 27 patients (92.6%), including 10 of 10 stenoses and 15 of 17 occlusions. Paired VAS data were available in 23 patients. Median VAS score decreased from 8 (IQR, 8-9.5) at baseline to 1 (IQR, 0-2) at 4 weeks (P < 0.001), with a Hodges-Lehmann median reduction of 7.5 points (95% CI, 6.5-8.0). Median follow-up was 16 months (IQR, 12-20). Kaplan-Meier estimated primary patency was 90.7% at 12 months. Assisted primary and secondary patency were 92.0% and 100%, respectively. No major mesenteric arterial complications, bowel resection, CMI-related death, or stent occlusion-related death occurred. CONCLUSION: In patients with atherosclerotic CMI, attempted endovascular SMA revascularization achieved high technical success, substantial early symptom relief, and favorable midterm patency. VAS assessment may provide a quantitative patient-centered measure that complements imaging-based follow-up.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Türksayar O, Cingöz M, Tütüncüoğlu B, et al. Endovascular Stenting for Atherosclerotic Chronic Mesenteric Ischemia: Technical and Midterm Outcomes. Ann Vasc Surg. 2026. PMID: 42362018. doi:10.1016/j.avsg.2026.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。